Wed, Aug 27, 2014, 5:36 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • adamwangwang47 adamwangwang47 Apr 30, 2013 4:44 PM Flag

    GAAP operating expenses in 2013, including stock-based compensation, to be between $95 and $105 million

    Aegerion continues to expect total operating expenses, excluding stock-based compensation expense, to be between $75 and $85 million in 2013. The Company expects GAAP operating expenses in 2013, including stock-based compensation, to be between $95 and $105 million. Aegerion also expects global net product sales of $15 million to $25 million for FY 2013 and 250 to 300 patients on JUXTAPID therapy globally by year-end 2013.

    average priced paid might be $10000-20000/patient eventually, including mail order plus countries of India etc where IP is not covered

    Sentiment: Strong Sell

 
AEGR
32.54+1.57(+5.07%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.